1186607-83-9Relevant academic research and scientific papers
Pyrazolopyridine inhibitors of B-RafV600E. Part 1: The development of selective, orally bioavailable, and efficacious inhibitors
Wenglowsky, Steve,Ren, Li,Ahrendt, Kateri A.,Laird, Ellen R.,Aliagas, Ignacio,Alicke, Bruno,Buckmelter, Alex J.,Choo, Edna F.,Dinkel, Victoria,Feng, Bainian,Gloor, Susan L.,Gould, Stephen E.,Gross, Stefan,Gunzner-Toste, Janet,Hansen, Joshua D.,Hatzivassiliou, Georgia,Liu, Bonnie,Malesky, Kim,Mathieu, Simon,Newhouse, Brad,Raddatz, Nicholas J.,Ran, Yingqing,Rana, Sumeet,Randolph, Nikole,Risom, Tyler,Rudolph, Joachim,Savage, Scott,Selby, Leann T.,Shrag, Michael,Song, Kyung,Sturgis, Hillary L.,Voegtli, Walter C.,Wen, Zhaoyang,Willis, Brandon S.,Woessner, Richard D.,Wu, Wen-I,Young, Wendy B.,Grina, Jonas
scheme or table, p. 342 - 347 (2011/07/09)
The V600E mutation of B-Raf kinase results in constitutive activation of the MAPK signaling pathway and is present in approximately 7% of all cancers. Using structure-based design, a novel series of pyrazolopyridine inhibitors of B-RafV600E was
PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS
-
, (2009/10/22)
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
